Triple-negative breast cancer (TNBC), representing approximately 15–20% of all breast cancer (BC) diagnosed worldwide, is defined by the lack of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) [1,2]. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.